Roche purchases BioImagene for approx. $100M

Under the banner of Ventana Medical Systems, Roche has purchased BioImagene, a leader in digital pathology workflow and analysis. The deal, worth approximately $100 million, helps Roche's medical device division specialize and adapt in the increasingly competitive cancer-detection industry.

"With its leadership position in pathology and its global reach, Ventana is the ideal partner for BioImagene," says Ajit Singh, CEO of BioImagene, in a statement. "Ventana is already a leader in image analysis for breast cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories worldwide. In turn, BioImagene brings to Ventana additional capabilities for scanning and analysing tissue that are not possible in the glass-slide world."

BioImagene, privately held and based in Sunnyvale, CA, creates digital images of microscopic slides and the computer software to analyse them--thereby cutting down on the time and costs associated with diagnosing cancer.

- read the Roche release
- check out the InPharm article
- here's WSJ's coverage

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.